✦ LIBER ✦

Early combination therapy with bromocriptine and levodopa in parkinson's disease

✍ Scribed by Dr. Stewart A. Factor; William J. Weiner

Publisher: John Wiley and Sons
Year: 1993
Tongue: English
Weight: 588 KB
Volume: 8
Category: Article
ISSN: 0885-3185
DOI: 10.1002/mds.870080302

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The use of early combination therapy with bromocriptine (Br) and levodopa (LD) in Parkinson's disease is controversial. It has been suggested that treatment with this regimen would prevent or delay the onset of motor fluctuations and dyskinesia. Thus, some have recommended it as a standard of care. This recommendation is based on the theory that LD may accelerate the progression of PD and clinical experience using Br monotherapy in early Parkinson's disease, which suggested that Br causes fewer late complications. This article reviews these arguments and shows that the theories are uproven. A single, uncontrolled trial is often referred to as evidence for efficacy of early combination therapy. We critically review this and five other studies which have evaluated the treatment strategy. We show that the literature is often misleading and that these trials do not support the efficacy of early combination therapy. We conclude that there is no justifiable reason to use a combination of Br and LD in early parkinsonian patients.

📜 SIMILAR VOLUMES

Levodopa, bromocriptine and selegiline m

Levodopa, bromocriptine and selegiline modify cardiovascular responses in Parkinson's disease

✍ Tarja H. Haapaniemi; Mika A. Kallio; Juha T. Korpelainen; Kalervo Suominen; Uole 📂 Article 📅 2000 🏛 Springer 🌐 English ⚖ 232 KB

Levodopa response in early Parkinson's d

Levodopa response in early Parkinson's disease

✍ Robert A. Hauser; Peggy Auinger; David Oakes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 244 KB 👁 1 views

## Abstract To further characterize the short‐term levodopa response in early PD, we performed a retrospective analysis of the ELLDOPA study which randomized 361 early PD subjects to placebo, levodopa 150, 300, or 600 mg/day. We evaluated change in UPDRS motor scores (UPDRSm) from baseline to weeks

Comparing bromocriptine effects with lev

Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease

✍ Tomoyuki Uchiyama; Ryuji Sakakibara; Tatsuya Yamamoto; Takashi Ito; M Chiharu Ya 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 67 KB

## Abstract To evaluate the effects of bromocriptine on bladder function in Parkinson's disease (PD) patients and compare these effects with those of (L‐dopa). We recruited 8 patients with PD. Urodynamic study (UDS) was performed before and 1 hour after administering 100 mg L‐dopa/decarboxylase inh

Levodopa therapy and motor fluctuations

Levodopa therapy and motor fluctuations in Parkinson's disease

✍ J. A. Obeso; M. R. Luquin; F. Grandas; J. Vaamonde; J. M. Ínez Marcht Lage; J. D 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB 👁 2 views

Time course of loss of clinical benefit

Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson's disease

✍ Robert A. Hauser; William C. Koller; Jean P. Hubble; Teresita Malapira; Karen Bu 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

Quantitative description of loss of clin

Quantitative description of loss of clinical benefit following withdrawal of levodopa–carbidopa and bromocriptine in early Parkinson's disease

✍ Robert A. Hauser; Nicholas H.G. Holford 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

## Abstract In Parkinson's disease, effects of medications on the progression of the underlying disease can be assessed clinically by evaluating patients at baseline prior to treatment and at endpoint following medication washout. With this design, it is critical to employ a washout of sufficient d